- Management TeamNews
- Management TeamNews
Leadership team fully strengthened to drive next phase of development Leiden, The Netherlands, 12 november 2024 VarmX, a biotech company...
News & events
News & events
- News
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, has been awarded up...
- News
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that new...
- News
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment...
- News
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment...
- Scientific publications
Reversal of anticoagulation is important for safe usage of oral factor (F)Xa-inhibiting direct oral anticoagulants (FXa-DOACs).
...- News
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the completion...
- News
VarmX, Leiden based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis, today announced...
- News
VarmX announces publication in Nature Communications of groundbreaking snake venom inspired approach to restore blood clotting in patients using anticoagulants...
- Scientific publications
The absence of an adequate reversal strategy to prevent and stop potential life-threatening bleeding complications is a major drawback to...